Tarveda Therapeutics

Answer: Tarveda Therapeutics's phone number is 61********

Answer: Tarveda Therapeutics's official website is https://tarvedatx.com

Answer: Tarveda Therapeutics's revenue is $5 Million to $10 Million

Answer: Tarveda Therapeutics's SIC: 8731

Answer: Tarveda Therapeutics has 11-50 employees

Answer: Tarveda Therapeutics is in Biotechnology

Answer: Tarveda Therapeutics contact info: Phone number: 61******** Website: https://tarvedatx.com

Answer: Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells. The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor. Tarvedas first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment, but which remains relatively dormant in normal tissue. Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors. PEN-866 is a miniature drug conjugate that selectively binds to the activated form of HSP90 linked to a topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 has commenced its Phase 2a trial in various types of solid tumors. In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors.

Answer:

• LinkedIn